Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme
Corey Smith(QIMR Berghofer Medical Research Institute), Rajiv Khanna(QIMR Berghofer Medical Research Institute), George Ambalathingal(The University of Queensland), Sweera Rehan(QIMR Berghofer Medical Research Institute), Katherine Matthews, José Paulo Martins(The University of Queensland), Sriganesh Srihari(QIMR Berghofer Medical Research Institute), David Walker(St. Jude Children's Research Hospital), Katie E. Lineburg(QIMR Berghofer Medical Research Institute), Beth Morrison(Queensland Emergency Medicine Research Foundation), Archana Panikkar(QIMR Berghofer Medical Research Institute), Michelle A. Neller(QIMR Berghofer Medical Research Institute), Leone Beagley, Laëtitia Le Texier(QIMR Berghofer Medical Research Institute), Pauline Crooks(QIMR Berghofer Medical Research Institute)
Cited by 64
Related Papers
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
|Cancer Discovery|2019|272
Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients.
|Journal of Clinical Pathology|1984|261
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses
|Proceedings of the National Academy of Sciences|2004|235
BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies
|Clinical Microbiology Reviews|2017|226